1BD Stock Overview
A biotechnology company, engages in the research, development, manufacture, and supply of agarose-based separation products to purify proteins, enzymes, antibodies, peptides, and other biomolecules primarily in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bio-Works Technologies AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.054 |
| 52 Week High | SEK 0.61 |
| 52 Week Low | SEK 0.046 |
| Beta | 1.18 |
| 11 Month Change | 15.45% |
| 3 Month Change | -46.47% |
| 1 Year Change | -87.55% |
| 33 Year Change | -97.86% |
| 5 Year Change | n/a |
| Change since IPO | -94.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BD | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -9.1% | 2.4% | 0.8% |
| 1Y | -87.5% | -5.0% | 9.1% |
Return vs Industry: 1BD underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: 1BD underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 1BD volatility | |
|---|---|
| 1BD Average Weekly Movement | 20.6% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1BD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1BD's weekly volatility has decreased from 31% to 21% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 35 | Lone Carlbom | www.bio-works.com |
Bio-Works Technologies AB (publ), a biotechnology company, engages in the research, development, manufacture, and supply of agarose-based separation products to purify proteins, enzymes, antibodies, peptides, and other biomolecules primarily in Sweden. It offers activated and affinity resins; hydrophobic interaction chromatography resins; GoBio Mini columns; immobilized metal-ion affinity chromatography resins; ion exchange resins; desalting columns; RoboColumns and Optimo PRO 96 well screens; screening kits; and size exclusion chromatography resins. The company’s products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications.
Bio-Works Technologies AB (publ) Fundamentals Summary
| 1BD fundamental statistics | |
|---|---|
| Market cap | €6.01m |
| Earnings (TTM) | -€3.25m |
| Revenue (TTM) | €3.28m |
1.8x
P/S Ratio-1.8x
P/E RatioIs 1BD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BD income statement (TTM) | |
|---|---|
| Revenue | SEK 37.88m |
| Cost of Revenue | SEK 10.16m |
| Gross Profit | SEK 27.72m |
| Other Expenses | SEK 65.24m |
| Earnings | -SEK 37.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 73.18% |
| Net Profit Margin | -99.05% |
| Debt/Equity Ratio | 0% |
How did 1BD perform over the long term?
See historical performance and comparison